Last reviewed · How we verify
Cam2020 M2SR H3N2 influenza vaccine
Cam2020 M2SR H3N2 influenza vaccine is a Biologic drug developed by FluGen Inc. It is currently in Phase 1 development.
At a glance
| Generic name | Cam2020 M2SR H3N2 influenza vaccine |
|---|---|
| Sponsor | FluGen Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cam2020 M2SR H3N2 influenza vaccine CI brief — competitive landscape report
- Cam2020 M2SR H3N2 influenza vaccine updates RSS · CI watch RSS
- FluGen Inc portfolio CI
Frequently asked questions about Cam2020 M2SR H3N2 influenza vaccine
What is Cam2020 M2SR H3N2 influenza vaccine?
Cam2020 M2SR H3N2 influenza vaccine is a Biologic drug developed by FluGen Inc.
Who makes Cam2020 M2SR H3N2 influenza vaccine?
Cam2020 M2SR H3N2 influenza vaccine is developed by FluGen Inc (see full FluGen Inc pipeline at /company/flugen-inc).
What development phase is Cam2020 M2SR H3N2 influenza vaccine in?
Cam2020 M2SR H3N2 influenza vaccine is in Phase 1.